Clinical trials: VZV
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07892989
- Testing
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Active Comparator Vaccine
- Volunteers
- 496 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Neuralgia, Pain
Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain
The purpose of this study is to gain initial information on the tolerability of high-dose capsaicin patches in patients with Painful Postherpetic Neuralgia.
- Conditions
- Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
- Trial name
- NCT00034710
- Testing
- Capsaicin Patch
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- NeurogesX
Chickenpox
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
This study aims to assess the immune response and safety of GSK's candidate chickenpox and marketed MMR vaccines when given to children 12 to 15 months of age via a muscle injection.
- Trial name
- NCT06855160
- Testing
- Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine
- Where
- 22 sites in United States, Belgium and 5 more
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Postherpetic Neuralgia
Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
- Trial name
- NCT00652184
- Testing
- valaciclovir
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- aRigen Pharmaceuticals, Inc.
Kidney Transplant; Complications, Varicella Zoster Virus Infection
Herpes Virus Infections in Kidney Transplant Patients
Kidney transplant recipients are at increased risk of infections, including Varicella-zoster virus (VZV) infections. Vaccination against VZV is routinely offered to all kidney transplant recipients and candidates in Denmark.
- Conditions
- Kidney Transplant; Complications, Varicella Zoster Virus Infection, Vaccine-Preventable Diseases
- Trial name
- HINT (NCT05604911)
- Where
- 5 sites in Denmark
- Volunteers
- 280 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Chickenpox
Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children
The purpose of this study is to observe the persistence of protection, duration of protection, safety and breakthrough infection rates afforded by live attenuated varicella vaccine in children over a 5-year period.
- Trial name
- NCT01982409
- Testing
- Live Attenuated Varicella Vaccine
- Where
- China
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Changchun Changsheng Life Science and Technology Co., Ltd.
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Varicella
A Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Profile of TNM005 in Healthy Adult Subjectsy
The purpose of this clinical trial is to evaluate the safety and tolerability of TNM005 following a single dose by intramuscular (IM) administration in healthy adult subjects The main questions it aims to answer are:1.
- Trial name
- NCT06068608
- Testing
- TNM005, VariZIG
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Zhuhai Trinomab Pharmaceutical Co., Ltd.
Herpes Zoster
A Clinical Study of a Zoster Vaccine in Healthy Adults >= 40 Years
Varicella-zoster virus (VZV) is a herpesvirus that causes two distinct clinical syndromes.Primary infection is manifested as varicella (chickenpox), whereas reactivation of latent VZV results in a localized eruption known as…
- Trial name
- NCT04072497
- Testing
- One shot of the zoster vaccine, One shot of the varicella vaccine
- Where
- China
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Meningococcal Meningitis, Measles
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
This is a Phase III, modified single-blind, randomized, parallel-group, multicenter, comparative trial in the United States designed to evaluate the immunogenicity and safety of two doses of Menactra vaccine administered alone…
- Conditions
- Meningococcal Meningitis, Measles, Mumps, Rubella
- Trial name
- NCT00384397
- Testing
- Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
- Where
- 39 sites in United States
- Volunteers
- 1,128 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Disorders
Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine
This study will provide information regarding the sequential administration of two vaccines adjuvanted with AS01. The aim of this study is to understand immunogenicity and safety of NTHi-Mcat vaccine when administered…
- Trial name
- NCT03894969
- Testing
- GSK's investigational non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) multi-antigen vaccine (GSK3277511A) adjuvanted with AS01E, Shingrix GSK's lyophilized formulation of the herpes zoster (HZ) vaccine (GSK1437173A)
- Where
- 14 sites in Estonia, Finland and 3 more
- Volunteers
- 541 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Multidisciplinary Hospital-Territory Vaccine Center: a Model for Achieving the Herpes Zoster Vaccine Coverage
The National Vaccination Program, updated by the Ministry of Health in 2021, provides a new vaccination opportunity for frail patients against Herpes zoster virus (HZ).
- Trial name
- CeVOT-Her-Zo (NCT06334861)
- Testing
- Herpes Zoster adjuvanted recombinant vaccine
- Where
- Italy
- Volunteers
- 178 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prevention of Herpes Zoster
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
- Trial name
- NCT06961721
- Testing
- Herpes Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Changchun BCHT Biotechnology Co.
Multiple Sclerosis, Hypogammaglobulinemia
Rituximab-Induced Hypogammaglobulinemia in Multiple Sclerosis
B cells are considered major contributors to multiple sclerosis (MS) pathogenesis, a role that has taken on renewed importance with the advent of B-cell-depleting therapies.
- Trial name
- NCT04283747
- Testing
- Serum immunoglobulin titer
- Where
- Iran
- Volunteers
- 170 people
- Sponsor
- Mazandaran University of Medical Sciences
Post Herpetic Neuralgia (PHN)
Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN).
- Trial name
- NCT07123987
- Testing
- transcutaneous auricular vagus nerve stimulation (taVNS), traditional medical treatment for PHN
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Mohamed Hosny Ismail Easa
Varicella
Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui Province
This is Phase 4 clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the protective effect of varicella vaccine in children…
- Trial name
- NCT05470855
- Testing
- Live attenuated varicella vaccine
- Where
- 5 sites in China
- Volunteers
- 45,400 people
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Chickenpox
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
The purpose of this study is to assess immune response and safety of various potencies of an investigational chickenpox vaccine given to healthy children 12 to 15 months of age.
- Trial name
- NCT05084508
- Testing
- Investigational varicella vaccine low potency, Investigational varicella vaccine medium potency, Investigational varicella vaccine high potency
- Where
- 51 sites in United States, Estonia and 4 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal…
- Trial name
- NCT07481604
- Testing
- Shingrix, CVI-VZV-001
- Where
- 7 sites in South Korea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Aribio Lab Co., Ltd.
Herpes Zoster
Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects
Based on the results of a previous clinical PhaseI/II study, GSK1437173A is the lead GSK candidate Herpes Zoster (HZ) vaccine to prevent episodes of HZ (shingles).
- Trial name
- NCT00434577
- Testing
- Herpes Zoster vaccine GSK1437173A Low Dose, Herpes Zoster vaccine GSK1437173A Medium Dose, Herpes Zoster vaccine GSK1437173A High Dose
- Where
- 11 sites in Czechia, Germany and 2 more
- Volunteers
- 715 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline